{"schema_version":"secwatch.filing_event.v1","accession":"0001999371-24-004298","form_type":"8-K","ticker":"TNXP","cik":"0001430306","company_name":"Tonix Pharmaceuticals Holding Corp.","filed_at":"2024-04-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.381776+00:00","generated_at":"2026-06-04T04:26:23.966664+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Tonix Q4 2023 net loss $27.3M; cash down to $24.9M; Tonmya NDA on track for H2 2024","bullets":["Q4 2023 net loss $27.3M ($0.86/share) vs $34.1M ($3.42) in Q4 2022; full year net product revenue $7.8M.","Cash and equivalents $24.9M at Dec 31, 2023 vs $120.2M at Dec 31, 2022; net cash used in operations $102M.","Pre-NDA meeting with FDA for Tonmya (cyclobenzaprine SL) for fibromyalgia scheduled Q2 2024; NDA submission planned H2 2024.","Raised $4.4M in registered direct offering on March 28, 2024; also $11M term loan executed Dec 2023.","Completed transition to fully integrated pharma with marketed migraine products Zembrace and Tosymra."],"urls":{"canonical":"https://secwatch.observer/filing/0001999371-24-004298","json":"https://secwatch.observer/filing/0001999371-24-004298.json","markdown":"https://secwatch.observer/filing/0001999371-24-004298.md","text":"https://secwatch.observer/filing/0001999371-24-004298.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1430306/000199937124004298/0001999371-24-004298-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1430306/000199937124004298/tnxp_8k-040124.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T04:26:23.966664+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4ceb06abf4a55bc1cfccaf400480f86cf0a363cb","claim":"Tonix Pharmaceuticals Holding Corp. reported financial results for the fourth quarter and full year ended December 31, 2023.","evidence_excerpt":"On April 1, 2024, Tonix Pharmaceuticals Holding Corp. (the “Company”) announced its operating results for the quarter and year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1430306/000199937124004298/0001999371-24-004298-index.htm","confidence":0.8,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}